Q1 FY 2027 saw 13.7% year-on-year revenue growth, strong pharma and clinical research performance, and stable margins despite global headwinds. Biologics commercialization began, with exports at 40% of revenue and robust cash reserves supporting disciplined CapEx.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.